<DOC>
	<DOC>NCT01914159</DOC>
	<brief_summary>The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.</brief_summary>
	<brief_title>Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis of a pigment epithelial tear secondary to agerelated macular degeneration Written informed consent Time of diagnosis more than 6 months before study recruitment Ocular surgery of the study eye within 1 month before study recruitment Extensive subretinal fibrosis or retinal atrophy of the study eye Significant opacification of optical media of the study eye Uncontrolled glaucoma of the study eye Active ocular inflammation of the study eye Bestcorrected visual acuity of the contralateral eye below 20/200 Concurrent ocular or systemic therapy with other vascular endothelial growth factor (VEGF)inhibitory drugs</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>